Microsystems for Cancer Therapeutic Approach

A special issue of Micromachines (ISSN 2072-666X). This special issue belongs to the section "B:Biology and Biomedicine".

Deadline for manuscript submissions: closed (1 March 2021) | Viewed by 4635

Special Issue Editors


E-Mail Website
Guest Editor
1. CNRS/IIS/COL/Lille University, SMMiL-E Project, CNRS Délégation Nord-Pas de Calais et Picardie, 2 rue de Canonniers, CEDEX, 59046 Lille, France
2. LIMMS/CNRS-IIS, Institute of Industrial Science, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8505, Japan
Interests: BioMEMS and cancer; microsystems technologies; actuators and sensors; biomedical micro devices; biomechanical and bioelectrical cell measurements; simulation and analysis

E-Mail Website
Guest Editor
Yncréa Hauts de France and IEMN UMR8520, F-59000 Lille, France
Interests: BioMEMS; microsystems; microfluidics; single cell analysis; biophysical characterization

Special Issue Information

Dear Colleagues,

According to the World Health Organization, cancer, responsible for an estimated 9.4 million deaths per year, is the second leading cause of death globally. Despite intensive research programs, while many other major killers like heart disease and pneumonia have shown dramatic improvements and spectacular advances in treatment, the mortality and morbidity rates for most cancers have remained almost unchanged.

Cancer arises from the cellular transformation into tumour cells in a multistage process that generally progresses from a pre-cancerous lesion to a malignant tumour. These changes are the result of the interaction between a person's genetic factors and intricate multiscale molecular and cellular mechanisms triggered in cell environment, tissues and organs.

The development of smart microdevices (lab on chip, bioMEMS, and microfluidics) allowed for the study of cancer biology at the proper scale to characterise cancer cells, analyse metastatic mechanisms and mimic tumour microenvironment, among others. Nevertheless, as mentioned, the research priority has to be set far beyond microtechnologies, approaching the translational level to allow exchanges between fundamental research and clinics.

This Special Issue on Microsystems for Cancer Therapeutic Approach invites manuscripts on research aiming to develop clinically-oriented experiments and assays in microdevices. Papers involving cancer surgery (e.g., margin detection, and neo-tissues), chemotherapy (e.g., drug development on realistic in vitro models), immunotherapy (e.g., high-throughput cellular interaction screening), and radiotherapy (e.g., enhanced radiative effect and selectivity) are encouraged to emphasize the translational nature of the research on cancer diagnostics, treatment, care, and monitoring. The project design with clinicians, the evaluation of the translational opportunity and the planned route toward the preclinical assays are also welcome to be discussed in the manuscripts.

Prof. Dr. Dominique Collard
Prof. Dr. Cagatay Tarhan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Micromachines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Microsystems for Biology and Life Science (BioMEMS)
  • Lab on Chip
  • Cancer
  • Therapeutic Approach
  • Cancer Surgery
  • Chemotherapy
  • Cancer Immunotherapy
  • Radiotherapy
  • Tumour on Chip
  • Tumour Microenvironment
  • Inflammation and Cancer
  • Blood Vessel/Tumour Interactions
  • Tumosphere
  • Cell Analysis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 912 KiB  
Review
Potential of Drug Efficacy Evaluation in Lung and Kidney Cancer Models Using Organ-on-a-Chip Technology
by Seong-Hye Hwang, Sangchul Lee, Jee Yoon Park, Jessie Sungyun Jeon, Young-Jae Cho and Sejoong Kim
Micromachines 2021, 12(2), 215; https://0-doi-org.brum.beds.ac.uk/10.3390/mi12020215 - 21 Feb 2021
Cited by 13 | Viewed by 4239
Abstract
Organ-on-a-chip (OoC) is an exponential technology with the potential to revolutionize disease, toxicology research, and drug discovery. Recent advances in OoC could be utilized for drug screening in disease models to evaluate the efficacy of new therapies and support new tools for the [...] Read more.
Organ-on-a-chip (OoC) is an exponential technology with the potential to revolutionize disease, toxicology research, and drug discovery. Recent advances in OoC could be utilized for drug screening in disease models to evaluate the efficacy of new therapies and support new tools for the understanding of disease mechanisms. Rigorous validation of this technology is required to determine whether OoC models may represent human-relevant physiology and predict clinical outcomes in target disease models. Achievements in the OoC field could reveal exciting new avenues for drug development and discovery. This review attempts to highlight the benefits of OoC as per our understanding of the cellular and molecular pathways in lung and kidney cancer models, and discusses the challenges in evaluating drug efficacy. Full article
(This article belongs to the Special Issue Microsystems for Cancer Therapeutic Approach)
Show Figures

Figure 1

Back to TopTop